Member Info for EarlofAim

Bored traders will sell and go after something with more potential

one is I've posted

Couldn't get a quote on the bell IG put redx on Auction,

then sellers gave opportunity at 23p

nice one sellers.

New commerical service from OptiMAL® programme

Fusion Antibodies plc (AIM: FAB), specialists in pre-clinical antibody discovery, engineering and supply for both therapeutic drug and diagnostic applications, announces an update on the Company's AI/ML-AbTM (pronounced AIM-Lab) service offering.

On 19 May 2023, the Company announced that it had signed memoranda of understanding with two AI/ML (artificial intelligence and machine learning) companies. The Company is pleased to announce that that is has now signed an agreement (the "Agreement") with the first of the companies, a leading US-based AI/ML business, to support Fusion's new AI/ML-AbTM service offering. Pursuant to the Agreement, it is envisaged that both parties will co-market the combined service offerings covering both the in silico AI/ML design of antibodies and their production and evaluation in vitro

AstraZeneca bets $247M AI can create a cancer-fighting antibody

market missing FAB here

AstraZeneca investing in the $247m

FAB doing the similar thing!!!

https://www.theregister.com/2023/12/04/astrazeneca_absci_cancer/

AstraZeneca bets $247M AI can create a cancer-fighting antibody

market missing FAB here

AstraZeneca investing in the $247m

FAB doing the similar thing!!!

#redx well done holders

This is why #biotech companies can reap big rewards when industry experts sees potential

Another on under the radar company and under valued is #fab

@FsnAntibodies

Game changer news coming

USA @theNCI taken #fab seriously

Mcap £2.8m could become £25m

Over 30,000 trades last few days and week

not a single TR1 since helium was acknowledged!

what does this tells you, most are trading the crap out of this stock.

What's next for HE1?

Orphan period?

silence?

non activity?

Redx, Rns gives the likes of FAB confidence and

well done redx holders

Redx, Rns gives the likes of FAB confidence

Some so call Posters don't have a clue how to value bio tech companies with huge potentials.

Remember this, Investors don't make investment decisions on AIM Biotech or Nasdaq Biotech using Revenues and profits

that's not the criteria, the criteria is how big can t

it become in the future,

Future for FAB is lookin Fabulous, Along the way FAB are getting payments which are bonus,

Value is what this all about, this ain't like investing In AstraZeneca or GSK,

revenue is not what drives sp, it's the Potential like Optimal®

40 bagger according to spongeshare.com

Read below

https://spongeshare.com/2023/06/06/trade-idea-fusion-antibodies-40-bags-back-to-highs-and-reasons-why-it-just-could-do-that/

Some In the know suggested Optimal® has a minimum valuation of £50M

that's almost 19 bagger from current levels.

take your pick

or

So one says He1 not discovered officially.... Lmao... so rns was BS and Sp rose some 13 bags on what exactly?

the other one thinks I'm Pompous... jeez yes I'll take that.....

what I've posted will come true

Sp decline,

volume decrease

HE1 will be at an Orphan period.

watch and learn,

in he meantime look what I've posted for The company and it's mega re rate coming

Some In the know suggested Optimal® has a minimum valuation of £50M

that's almost 19 bagger from current levels.

Value the company for its Products and Tech, not what happened in the past

Each day Volume will decrease from the peak

so Monday, Friday was over 10 thousand Trades, Tuesday 7000 already 30% reduction in the volume

Orphan period is upon He1

Orphan period, after the ecstasy result

seen this many times

.....

Sp will slide until the concrete news on Funding, Commercialisation, JV partner,

when will the first Helium be ready for sale

.. etc etc

hence this is called The Orphan period in mining Industry.

Some s Posters don't have a clue how to value bio tech companies with huge potentials.

Remember this, Investors don't make investment decisions on AIM Biotech or Nasdaq Biotech using Revenues and profits

that's not the criteria, the criteria is how big can it become in the future,

Future for FAB is lookin Fabulous, Along the way FAB are getting payments which are bonus,

Value is what this all about, this ain't like investing In AstraZeneca or GSK,

revenue is not what drives sp, it's the Potential like Optimal®

which only biotech would understand.

Some so call Posters don't have a clue how to value bio tech companies with huge potentials.

Remember this, Investors don't make investment decisions on AIM Biotech or Nasdaq Biotech using Revenues and profits

that's not the criteria, the criteria is how big can t

it become in the future,

Future for FAB is lookin Fabulous, Along the way FAB are getting payments which are bonus,

Value is what this all about, this ain't like investing In AstraZeneca or GSK,

revenue is not what drives sp, it's the Potential like Optimal®

which only biotech would understand.

Seen that last few days trades, someone is loading up, whilst traders sell for small profits, I do think FAB has a big move coming soon.

CEO needs to get few more deals so placing not needed in the next 8 months or so.

Neither I wrote the article nor the 40 bagger was my idea, I'm posting what some in the know reckons this has got.

who can rule out that one of the bigger players in the sector won't gobble Fusion up?

Sp is ridiculously cheap.

Optimal is the only platform in the world, CEO said

this should be trading at 15p but market mechanics stopped it rising today.

GLA and Dyor before its too late

Old article, but the business tech isn't old, which means 40 bagger potential is more likely to happen than previously thought.

Mcap is ridiculously cheap.

Optimal on its own is valued in £50m region,

then other tech fusion-antibiotics-plc has.

yes 40 bagger article is old but Rome wasn't build in a day!